<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02097810</url>
  </required_header>
  <id_info>
    <org_study_id>RXDX-101-01</org_study_id>
    <secondary_id>GO40784</secondary_id>
    <nct_id>NCT02097810</nct_id>
  </id_info>
  <brief_title>Study of Oral RXDX-101 in Adult Patients With Locally Advanced or Metastatic Cancer Targeting NTRK1, NTRK2, NTRK3, ROS1, or ALK Molecular Alterations.</brief_title>
  <acronym>STARTRK-1</acronym>
  <official_title>A Phase 1, Multicenter, Open-Label Study of Oral Entrectinib (RXDX-101) in Adult Patients With Locally Advanced or Metastatic Cancer Confirmed to be Positive for NTRK1, NTRK2, NTRK3, ROS1, or ALK Molecular Alterations</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hoffmann-La Roche</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hoffmann-La Roche</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Entrectinib (RXDX-101) is an orally available inhibitor of the tyrosine kinases TrkA (coded&#xD;
      by the gene NTRK1), TrkB (coded by the gene NTRK2), TrkC (coded by the gene NTRK3), ROS1&#xD;
      (coded by the gene ROS1), and ALK (coded by the gene ALK). Molecular alterations to one or&#xD;
      more of these targets are present in several different tumor types, including non-small cell&#xD;
      lung cancer (NSCLC), colorectal cancer (CRC), prostate cancer, papillary thyroid cancer,&#xD;
      pancreatic cancer, and neuroblastoma. Patients with locally advanced or metastatic cancer&#xD;
      with a detectable molecular alteration in targets of interest may be eligible for enrollment.&#xD;
&#xD;
      Phase 1 will assess safety and tolerability of entrectinib via standard dose escalation&#xD;
      scheme and determine the recommended Phase 2 dose. Safety and efficacy will be assessed in&#xD;
      the dose expansion portion of the study.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">July 28, 2014</start_date>
  <completion_date type="Actual">June 2, 2020</completion_date>
  <primary_completion_date type="Actual">June 2, 2020</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Dose-Limiting Toxicity (DLT)</measure>
    <time_frame>28 days following first dose of entrectinib</time_frame>
    <description>Determine dose-limiting toxicities of entrectinib.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Maximum Tolerated Dose (MTD)</measure>
    <time_frame>28 days following first dose of entrectinib</time_frame>
    <description>Determine MTD of entrectinib</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Recommended Phase 2 Dose (RP2D)</measure>
    <time_frame>Approx. 6 months</time_frame>
    <description>Determine RP2D of entrectinib.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Overall Response Rate (ORR) in Dose Expansion</measure>
    <time_frame>Approx. 2 months</time_frame>
    <description>Per RECIST v1.1 as assessed by Investigator.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Plasma Concentrations of Entrectinib</measure>
    <time_frame>Cycle 1 Days 1, 7, 14, 28</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease Control</measure>
    <time_frame>Approx. 2 years</time_frame>
    <description>Per RECIST v1.1 as assessed by Investigator.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of Response</measure>
    <time_frame>Approx. 2 years</time_frame>
    <description>Per RECIST v1.1 as assessed by Investigator.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival (OS)</measure>
    <time_frame>Approx. 2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-Free Survival (PFS)</measure>
    <time_frame>Approx. 2 years</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">84</enrollment>
  <condition>Locally Advanced Solid Tumors</condition>
  <condition>Metastatic Solid Tumors</condition>
  <arm_group>
    <arm_group_label>Entrectinib (RXDX-101)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Oral entrectinib (RXDX-101)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Entrectinib</intervention_name>
    <arm_group_label>Entrectinib (RXDX-101)</arm_group_label>
    <other_name>TrkA/TrkB/TrkC/ROS1/ALK inhibitor</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Key Inclusion Criteria:&#xD;
&#xD;
          -  Histologically or cytologically confirmed diagnosis of locally advanced or metastatic&#xD;
             solid tumors that have a NTRK1, NTRK2, NTRK3, ROS1, or ALK molecular alteration.&#xD;
&#xD;
          -  Measurable disease according to RECIST version 1.1.&#xD;
&#xD;
          -  Prior cancer therapy is allowed, including crizotinib, ceritinib, and investigational&#xD;
             drugs.&#xD;
&#xD;
          -  Prior radiotherapy is allowed&#xD;
&#xD;
          -  Patients with controlled asymptomatic central nervous system involvement are allowed.&#xD;
&#xD;
          -  Resolution of all acute toxic effects (excluding alopecia) of any prior anti-cancer&#xD;
             therapy to National Cancer Institute Common Terminology Criteria for Adverse Events&#xD;
             (NCI CTCAE) Version 4.03 Grade less than or equal to 1.&#xD;
&#xD;
          -  Eastern Cooperative Oncology Group (ECOG) performance status (PS) ≤ 2.&#xD;
&#xD;
          -  Adult patients age 18 years or older.&#xD;
&#xD;
          -  Life expectancy of at least 3 months.&#xD;
&#xD;
        Key Exclusion Criteria:&#xD;
&#xD;
          -  Current participation in another therapeutic clinical trial.&#xD;
&#xD;
          -  Prior treatment with entrectinib.&#xD;
&#xD;
          -  History of prolonged QTc interval (e.g., repeated demonstration of a QTc interval &gt;&#xD;
             450 milliseconds).&#xD;
&#xD;
          -  History of additional risk factors for torsade de pointes (e.g., family history of&#xD;
             long QT syndrome).&#xD;
&#xD;
          -  Known active infections (bacterial, fungal, viral including HIV positivity).&#xD;
&#xD;
          -  Gastrointestinal disease (e.g., Crohn's disease, ulcerative colitis, or short gut&#xD;
             syndrome) or other malabsorption syndromes that would impact on drug absorption.&#xD;
&#xD;
          -  Known interstitial lung disease, interstitial fibrosis, or history of tyrosine kinase&#xD;
             inhibitor-induced pneumonitis.&#xD;
&#xD;
          -  Peripheral neuropathy ≥ Grade 2.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Clinical Trials</last_name>
    <role>Study Director</role>
    <affiliation>Hoffmann-La Roche</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>UC Irvine Medical Center</name>
      <address>
        <city>Orange</city>
        <state>California</state>
        <zip>92868</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of California, San Francisco, Helen Diller Family Comprehensive Cancer Center</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94158</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Of Colorado</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80045</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Georgetown University Medical Center</name>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <zip>20007</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Florida Cancer Specialists - Sarasota</name>
      <address>
        <city>Sarasota</city>
        <state>Florida</state>
        <zip>34232</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Massachusetts General Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan Kettering Cancer Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10065</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tennessee Oncology</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37203</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Texas M.D. Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Samsung Medical Center</name>
      <address>
        <city>Seoul</city>
        <zip>06531</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
    <country>United States</country>
  </location_countries>
  <removed_countries>
    <country>Spain</country>
  </removed_countries>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>March 21, 2014</study_first_submitted>
  <study_first_submitted_qc>March 24, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 27, 2014</study_first_posted>
  <last_update_submitted>June 7, 2021</last_update_submitted>
  <last_update_submitted_qc>June 7, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 9, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasm Metastasis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Entrectinib</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

